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AbstrAct:
Aberrant Kras signaling is observed in a high percentage of human lung cancers while 
activating  mutations  in  the  Wnt/β-catenin  signaling  pathway  are  only  rarely  found.  Our 
recent work has shown that the combined activation of both Kras and Wnt/β-catenin 
signaling leads to a dramatic increase in both tumor incidence and size. Moreover, 
lung tumors generated by the combined activation of both of these pathways exhibit a 
distinct phenotype similar to embryonic progenitors found in the developing lung. Thus, 
combinatorial activation of Kras and Wnt/β-catenin pathways leads to a significant 
increase in lung tumor formation characterized by a more progenitor like phenotype.
The “multiple hit” hypothesis of cancer pathogenesis 
has long been favorably viewed as a reasonable 
explanation of the relative rarity of many cancers. This 
hypothesis is derived from multiple lines of thought. 
For instance, two carcinogens, applied in sequence, are 
often more successful at initiating cancer in experimental 
animals than application of a single carcinogen during 
the same time [1, 2]. Another line of evidence comes 
from epidemiological observations of a linear correlation 
between the rate of cancer death and the patients age [3, 4]. 
Lung cancer is one of the leading causes of cancer death in 
the Western world. Although the majority of lung cancers 
are associated with cigarette smoking, only a minority of 
smokers end up having lung cancer. This suggests that 
there are other genetic or environmental causes that drive 
the high incidence of lung cancer. A recent report from 
our laboratory suggests that the “multiple hit” model of 
cancer is also useful in explaining the combined effects 
of co-activation of β-catenin and an oncogenic K-ras on 
lung tumorigenesis. 
While  Wnt/β-catenin  pathway  has  been  causally 
linked to colon and skin cancer in the past, its role in 
the development of lung cancer has been less clear [5, 
6]. There is significant interest in exploring the role of 
Wnt signaling in cancer and many drug discovery efforts 
are underway to block the pathway in multiple types of 
cancers  [7].  Previous  reports  have  shown  that  Wnt/β-
catenin activation in postnatal bronchiolar lung epithelium 
is ineffective in inducing lung tumor formation [8]. 
However, studies have linked Wnt/β-catenin activation 
to increased lung tumors metastasis and proliferation [9]. 
Despite these and other findings, little is understood about 
both the ability of activated Wnt/β-catenin signaling to 
promote lung tumorigenesis and which cell lineages within 
the complex milieu of the lung epithelia are susceptible to 
oncogenic transformation by Wnt signaling. 
Taking advantage of cell lineage specific cre lines 
for the secretory epithelium of the upper airways (CC10-
cre, [10]), we recently showed that while activation of 
β-catenin alone using  the Ctnnb1Δ(ex3) mice which will 
delete important regulatory phosphorylation sites within 
β-catenin that inhibit its function in Wnt signaling upon 
cre mediated recombination, has little effect on lung 
tumor formation, co-activation of both oncogenic K-ras 
and  activated  β-catenin  leads  to  far  more  aggressive 
tumor formation than when either pathway is activated 
alone [11]. Until recently, the available cre lines that could 
be used in the postnatal lung were not specific for any 
of the various epithelial lineages that populate the lung 
airways in a distinct proximal-distal manner. However, Li 
et. al. recently showed that when the cre recombinase is 
knocked into the Clara Cell 10 (CC10) kilodalton protein 
gene, cre recombinase can be expressed postnataly in a 
Clara or secetory cell specific fashion in the lung [10]. 
This line is similar to that reported by Rawlins et. al. 
which used a tamoxifen inducible version of cre instead 
of a constitutive version [12]. The advantage of these new 
cre lines is that investigators can address in a cell specific 
fashion the consequences of oncogene activation in the 
postnatal lung, specifically the secretory epithelium.Oncotarget 2011; 2:  569 - 574 570 www.impactjournals.com/oncotarget
Using the constitutive CC10-cre line, our group 
showed  that  β-catenin  activation  had  little  effect  on 
secretory epithelial proliferation or tumor formation 
[10, 11]. This is in agreement with previous reports and 
suggests  that  Wnt/β-catenin  activation  in  the  secretory 
epithelium of the lung is not normally an oncogenic event. 
To determine whether activation of another oncogenic 
pathway would result in tumor development originating 
in the secretory epithelium, we next expressed the 
G12D  oncogenic  form  of  Kras  (KrasG12D)  using  the 
CC10-cre line. K-ras mutations have been described in 
approximately 21% of lung cancers and are thus one of the 
most common neoplastic mutations found in lung cancers 
[13, 14]. Previous studies from Kim et. al. have indicated 
the presence of a bronchioalveolar stem cell (BASC) as 
a potential cancer stem cell in the lung [15]. Expression 
of KrasG12D in these cells leads to formation of focal 
hyperplasitic regions and adenomas [16, 17]. However, 
none  of  these  studies  asked  specifically  whether  such 
tumor initiation originated in the secretory epithelium. 
In our studies, expression of KrasG12D lead to distinct 
areas of epithelial hyperplasia with some of these regions 
forming adenomas by 3-4 months of age. However, we 
did not observe the presence of lung adenocarcinomas in 
these mice.
Lung tumors associated with Kras activation, both 
in humans and mice, show a great deal of phenotypic 
variation. This suggests the presence of other factors that 
can inhibit or promote Kras induced tumorigenesis in the 
lung. Therefore, we generated mice that expressed both 
KrasG12D and the activated β-catenin allele Ctnnb1Δ(ex3). 
In these compound mutant animals, lung tumors developed 
rapidly and often progressed to the adenocarcinoma stage. 
These tumors were larger and, interestingly, had decreased 
expression of secretory epithelial markers such as CC10 
and increased expression of alveolar epithelial markers 
such as surfactant protein C (Sftpc). Despite these changes 
in gene expression, fate-mapping of the CC10-cre positive 
cells in this tumor model showed that the mutant cells did 
arise from CC10+ secretory epithelium.
Using gene profiling techniques, we demonstrated 
that the KrasG12D:Ctnnb1Δ(ex3) mutant tumors were 
distinctly different than either the KrasG12D or Ctnnb1Δ(ex3) 
mutants alone. One of the most interesting aspects of 
these tumors is their high level of similarity to distal 
embryonic lung endoderm progenitors. These embryonic 
endoderm cells express genes such as Sox9 and Id2 
which are extinguished in normal adult lung epithelium. 
Remarkably, the KrasG12D:Ctnnb1Δ(ex3) double mutant 
tumors expressed high levels of these markers. Moreover, 
KrasG12D:Ctnnb1Δ(ex3) double mutant tumors displayed 
decreased expression of Hopx, a transcription factor 
normally expressed at high levels in adult lung epithelium 
that has been suggested to be a tumor suppressor [18]. 
Thus,  activation  of  both  oncogenic  K-ras  and  Wnt/β-
catenin pathways leads to a trans-differentiation event 
in adult secretory epithelium, altering the phenotype to 
resemble distal embryonic lung endoderm during the 
early stages of lung development.
The idea that expression of an embryonic progenitor 
phenotype leads to a more aggressive form of lung cancer is 
supported by a recent report showing that a lung embryonic 
progenitor expression profile predicts a poor prognosis in 
lung adenocarcinoma [19]. The authors of this study used 
differential gene expression analysis between E11.5 and 
E17.5 distal lung endoderm progenitors and derived a list 
of 10 genes which are enriched at E11.5. Patients with 
decreased levels of these genes had a better survival rate 
that patients with increased expression of these genes. 
Although the genes we identified are not found in this list, 
the basic concept that a tumor that is more similar to early 
embryonic lung progenitors would be more aggressive 
and lead to worse survival is supported by these findings.
Figure 1: Model of airway epithelial phenotypic trans-
differentiation events in KrasG12D:ctnnb1Δ(ex3) double 
mutant lung tumors. Normal lung epithelium consists of 
both secretory cell lineages in the bronchiolar regions (Clara 
cells) as well as ciliated epithelium while the alveolar regions 
consist of both type 1 and type 2 pneumocytes (A). Expression 
of KrasG12D leads to expansion of secretory cells as well as 
BASC  cells  (B).  Expression  of  both  KrasG12D:Ctnnb1Δ(ex3) 
leads to a trans-differentiation event where secretory cells alter 
their phenotype to resemble distal endoderm progenitors found 
in the embryonic lung (C).
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Figure 2: Activation state 
of Wnt and K-ras pathways 
in airway epithelium of the 
lung. In normal airway epithelial 
secretory cells, the Wnt pathway is 
not  activated  and  K-ras  signaling 
is not constitutively active (A). 
Expression  of  both  KrasG12D 
and  Ctnnb1Δ(ex3) activated alleles 
leads to expression of host of 
target genes which cooperate to 
trans-differentiate adult secretory 
epithelium to an embryonic distal 
endoderm progenitor phenotype 
(B). The resulting alterations in 
both pathways leads to decreased 
E-cadherin expression which may 
be due to sequestering of β-catenin 
away form the cell-cell junctions 
to the Wnt pathway and decreasing 
stability of the cadherin-catenin 
complex.
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These changes are interesting and present new 
information regarding the role of Wnt/β-catenin in lung 
cancer. However, the finding that certain genes representing 
the distal embryonic lung endoderm gene expression 
profile including Sox9 were also upregulated in several 
human lung cancers including lung adenocarcinomas 
further extends the idea of an increased embryonic gene 
expression profile that could be a common hallmark of 
human lung cancer.
Several lines of evidence indicate that Wnt/β-catenin 
signaling is crucial for distal lung endoderm development 
in the lung. Loss of Wnt2/2b or β-catenin prior to lung 
endoderm specification leads to complete lung agenesis 
including loss of tracheal development and loss of 
induction of Nkx2.1 expression [20]. Slightly later in 
development, loss of β-catenin or expression of the Wnt 
inhibitor Dkk1, leads to decreased distal lung endoderm 
development and expanded proximal airway endoderm 
development [21, 22]. These data point to an essential role 
for Wnt/β-catenin in specification and/or maintenance of 
the distal lung endoderm. This concept is in line with what 
is observed in the KrasG12D:Ctnnb1Δ(ex3) double mutant 
lung tumors where the combined expression of oncogenic 
K-ras  and  β-catenin  causes  a  trans-differentiation  of 
proximal secretory epithelium to an embryonic distal lung 
endoderm phenotype. Thus, in the presence of activated 
Wnt/β-catenin signaling, the default phenotype in the lung 
epithelium may be that displayed by embryonic distal 
lung endoderm progenitors even if the oncogenic event 
occurs in proximal secretory epithelium.
Our  results  suggest  that  activation  of  β-catenin 
signaling in the presence of another oncogenic 
mutation such as KrasG12D, recapitulates some of the 
developmental  effects  of  Wnt/β-catenin  signaling.  The 
ability of β-catenin and KrasG12D to alter the bronchiolar 
epithelial phenotype to a distal embryonic lung endoderm 
phenotype supports the idea that Wnt/β-catenin signaling 
is necessary and sufficient to drive distal lung endoderm 
development. Although previous studies have not reported 
increased tumor formation by ectopic activation of 
β-catenin signaling in the postnatal lung, several reports 
have shown that embryonic activation of Wnt/β-catenin 
signaling can lead to lung epithelial dysplasia as well 
as ectopic reprogramming of stomach endoderm to the 
lung lineage. Expression of activated β-catenin starting 
at E14.5 in the fetal lung caused pulmonary adenomatous 
tumors in a subset of mice, however, the incidence of 
tumors was low, indicating that other epigenetic or genetic 
changes must occur to promote tumor initiation and/or 
progression [22]. Mutant lungs expressing the Ctnnb1Δ(ex3) 
allele after lung specification using the Nkx2.1-cre line 
also showed formation of polyp like structures indicating 
a precancerous lesion [23]. Thus, the timing of Wnt/β-
catenin activation likely plays an important role as to 
whether tumors or precancerous lesions will form in the 
lung.
There have been a few reports showing correlation 
between increased lung tumor formation and mutations 
or changes in expression of Wnt signaling components. 
Dkk3, an inhibitor of the Wnt/β-catenin pathway which is 
highly expressed in the normal lung has been found down-
regulated in lung tumors [24], while the ligand Wnt1 was 
determined to be a prognostic factor for patients with non 
small cell lung cancers, NSCLC [25]. Interestingly, human 
bronchiolar epithelial cells exposed to cigarette smoke 
have  a  significant  increase  in Wnt  signaling  activation 
[26]. This would suggest that cigarette smoking alone 
could prime lung epithelial cells for another oncogenic 
hit, possibly Kras mutations, that lead to lung cancer.
Lung cancer has been the leading cause of cancer 
deaths in the United States for many years [27, 28]. Despite 
ongoing research and improved clinical techniques for 
early detection, the one-year all-stage survival rate has 
only increased from 32% in 1973 to 41% in 1994 while 
the five-year survival has remained unchanged at 14%. We 
believe that the present findings could lead to screening for 
Wnt/β-catenin signaling activity as a prognostic indicator 
for the aggressiveness of lung tumors. Using screening 
assays for the activation state of the Wnt pathway in lung 
tumors could help to predict which tumors will develop 
into a more aggressive phenotype allowing for different 
treatments. Moreover, with the recent findings that Wnt/β-
catenin signaling are associated with increased lung tumor 
metastasis [9], such screening could also inform decisions 
on additional diagnostic tests and use of biopsies to detect 
metastatic spread of the tumors.
Given the enormous clinical burden that lung cancer 
represents, new advances are needed in both diagnosis 
and treatment. The finding that two of the most common 
oncogenic  pathways,  Wnt/β-catenin  and  Kras,  can 
cooperate to promote aggressive tumor development in 
mice suggests that these pathways should be analyzed 
together in lung tumor diagnosis. Combinatorial 
approaches using therapies directed towards the Wnt/β-
catenin pathway as well as the Kras pathways may also 
prove useful in combating lung cancer. Recent data 
suggests that rapamycin may be a useful treatment in 
certain  cancers  with  aberrant  Wnt/β-catnein  signaling 
activity [29-31]. This and other such approaches may 
provide new therapeutic ideas for lung cancer treatment 
in the future.
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